

Resource Summary Report

Generated by PRECISE-TBI on Jul 30, 2026

Beth Israel Deaconess Medical Center Precision RNA Medicine Delivery Unit Core Facility

RRID:SCR_024862

Type: Tool

Proper Citation

Beth Israel Deaconess Medical Center Precision RNA Medicine Delivery Unit Core Facility (RRID:SCR_024862)

Resource Information

URL: <https://www.bidmc.org/research/core-facilities/ncrna-core>

Proper Citation: Beth Israel Deaconess Medical Center Precision RNA Medicine Delivery Unit Core Facility (RRID:SCR_024862)

Description: Delivery Unit offers training and services on the NanoAssemblr Spark, NanoAssemblr Ignite+, and Malvern Zetasizer for the purpose of synthesis and characterisation of Lipid Nanoparticles (LNPs). The Zetasizer is able to read zeta potential and size of particles, including exosomes, liposomes, and LNPs.

Synonyms: Beth Israel Deaconess Medical Center Precision RNA Medicine Core - Delivery Unit, Precision RNA Medicine Core - Delivery Unit

Resource Type: access service resource, service resource, core facility

Keywords: ABRF

Resource Name: Beth Israel Deaconess Medical Center Precision RNA Medicine Delivery Unit Core Facility

Resource ID: SCR_024862

Alternate IDs: ABRF_2603

Alternate URLs: <https://coremarketplace.org/?FacilityID=2603&citation=1>

Record Creation Time: 20240111T050229+0000

Record Last Update: 20260729T044612+0000

Ratings and Alerts

No rating or validation information has been found for Beth Israel Deaconess Medical Center Precision RNA Medicine Delivery Unit Core Facility.

No alerts have been found for Beth Israel Deaconess Medical Center Precision RNA Medicine Delivery Unit Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Jagtap U, et al. (2025) MicroRNA-21 is a potential therapeutic agent targeting Tgfb1 and mitigating high-fat-diet-induced liver disease and cancer. Molecular therapy. Nucleic acids, 36(4), 102752.